APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Trial Profile

APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Apixaban (Primary) ; Dabigatran etexilate; Rivaroxaban
  • Indications Embolism; Stroke
  • Focus Therapeutic Use
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 22 Feb 2018 Planned End Date changed from 15 Nov 2017 to 31 Oct 2018.
    • 22 Feb 2018 Planned primary completion date changed from 15 Nov 2017 to 31 Jul 2018.
    • 02 Jun 2017 Planned End Date changed from 1 Dec 2016 to 15 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top